AustralieFrV1, PascalFrancis, Curation, bibRecord, 004980

Rheumatic heart disease

Identifieur interne : 004980 ( PascalFrancis/Curation ); précédent : 004979; suivant : 004981

Rheumatic heart disease

Auteurs : Eloi Marijon [France] ; Mariana Mirabel [France, Royaume-Uni] ; David S. Celermajer [Australie] ; Xavier Jouven [France, Royaume-Uni]

Source :

Lancet : (British edition) [ 0140-6736 ] ; 2012.

RBID : Pascal:12-0137539

Descripteurs français

Pascal (Inist)
- Rhumatisme, Médecine, Cardiopathie.
Wicri :
- topic : Médecine.

English descriptors

KwdEn :
- Heart disease, Medicine, Rheumatism.

Abstract

Rheumatic heart disease, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250000 deaths per year worldwide. The disease results from an abnormal autoimmune response to a group A streptococcal infection in a genetically susceptible host. Acute rheumatic fever-the precursor to rheumatic heart disease-can affect different organs and lead to irreversible valve damage and heart failure. Although penicillin is effective in the prevention of the disease, treatment of advanced stages uses up a vast amount of resources, which makes disease management especially challenging in emerging nations. Guidelines have therefore emphasised antibiotic prophylaxis against recurrent episodes of acute rheumatic fever, which seems feasible and cost effective. Early detection and targeted treatment might be possible if populations at risk for rheumatic heart disease in endemic areas are screened. In this setting, active surveillance with echocardiography-based screening might become very important.

A01	`01`	`1`		`@0 0140-6736`
A02	`01`			`@0 LANCAO`
A03		`1`		`@0 Lancet : (Br. ed.)`
A05				`@2 379`
A06				`@2 9819`
A08	`01`	`1`	`ENG`	`@1 Rheumatic heart disease`
A11	`01`	`1`		`@1 MARIJON (Eloi)`
A11	`02`	`1`		`@1 MIRABEL (Mariana)`
A11	`03`	`1`		`@1 CELERMAJER (David S.)`
A11	`04`	`1`		`@1 JOUVEN (Xavier)`
A14	`01`			`@1 Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`02`			`@1 Department of Cardiology, European Georges Pompidou Hospital @2 Paris @3 FRA @Z 1 aut. @Z 4 aut.`
A14	`03`			`@1 Paris Descartes University @2 Paris @3 FRA @Z 1 aut. @Z 2 aut. @Z 4 aut.`
A14	`04`			`@1 Maputo Heart Institute (ICOR), Maputo, Mozambique University College London @2 London @3 GBR @Z 2 aut. @Z 4 aut.`
A14	`05`			`@1 Sydney Medical School, University of Sydney, NSW @3 AUS @Z 3 aut.`
A20				`@1 953-964`
A21				`@1 2012`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 5004 @5 354000502896370220`
A44				`@0 0000 @1 © 2012 INIST-CNRS. All rights reserved.`
A45				`@0 141 ref.`
A47	`01`	`1`		`@0 12-0137539`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Lancet : (British edition)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 Rheumatic heart disease, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250000 deaths per year worldwide. The disease results from an abnormal autoimmune response to a group A streptococcal infection in a genetically susceptible host. Acute rheumatic fever-the precursor to rheumatic heart disease-can affect different organs and lead to irreversible valve damage and heart failure. Although penicillin is effective in the prevention of the disease, treatment of advanced stages uses up a vast amount of resources, which makes disease management especially challenging in emerging nations. Guidelines have therefore emphasised antibiotic prophylaxis against recurrent episodes of acute rheumatic fever, which seems feasible and cost effective. Early detection and targeted treatment might be possible if populations at risk for rheumatic heart disease in endemic areas are screened. In this setting, active surveillance with echocardiography-based screening might become very important.
C02	`01`	`X`		`@0 002B01`
C03	`01`	`X`	`FRE`	`@0 Rhumatisme @5 01`
C03	`01`	`X`	`ENG`	`@0 Rheumatism @5 01`
C03	`01`	`X`	`SPA`	`@0 Reumatismo @5 01`
C03	`02`	`X`	`FRE`	`@0 Médecine @5 02`
C03	`02`	`X`	`ENG`	`@0 Medicine @5 02`
C03	`02`	`X`	`SPA`	`@0 Medicina @5 02`
C03	`03`	`X`	`FRE`	`@0 Cardiopathie @5 04`
C03	`03`	`X`	`ENG`	`@0 Heart disease @5 04`
C03	`03`	`X`	`SPA`	`@0 Cardiopatía @5 04`
C07	`01`	`X`	`FRE`	`@0 Pathologie du système ostéoarticulaire @5 37`
C07	`01`	`X`	`ENG`	`@0 Diseases of the osteoarticular system @5 37`
C07	`01`	`X`	`SPA`	`@0 Sistema osteoarticular patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Pathologie de l'appareil circulatoire @5 38`
C07	`02`	`X`	`ENG`	`@0 Cardiovascular disease @5 38`
C07	`02`	`X`	`SPA`	`@0 Aparato circulatorio patología @5 38`
N21				`@1 107`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001532

Links to Exploration step

Pascal:12-0137539

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rheumatic heart disease</title>
<author><name sortKey="Marijon, Eloi" sort="Marijon, Eloi" uniqKey="Marijon E" first="Eloi" last="Marijon">Eloi Marijon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Cardiology, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mirabel, Mariana" sort="Mirabel, Mariana" uniqKey="Mirabel M" first="Mariana" last="Mirabel">Mariana Mirabel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Maputo Heart Institute (ICOR), Maputo, Mozambique  University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Celermajer, David S" sort="Celermajer, David S" uniqKey="Celermajer D" first="David S." last="Celermajer">David S. Celermajer</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Sydney Medical School, University of Sydney, NSW</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Jouven, Xavier" sort="Jouven, Xavier" uniqKey="Jouven X" first="Xavier" last="Jouven">Xavier Jouven</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Cardiology, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Maputo Heart Institute (ICOR), Maputo, Mozambique  University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0137539</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0137539 INIST</idno>
<idno type="RBID">Pascal:12-0137539</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001532</idno>
<idno type="wicri:Area/PascalFrancis/Curation">004980</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rheumatic heart disease</title>
<author><name sortKey="Marijon, Eloi" sort="Marijon, Eloi" uniqKey="Marijon E" first="Eloi" last="Marijon">Eloi Marijon</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Cardiology, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Mirabel, Mariana" sort="Mirabel, Mariana" uniqKey="Mirabel M" first="Mariana" last="Mirabel">Mariana Mirabel</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Maputo Heart Institute (ICOR), Maputo, Mozambique  University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
<author><name sortKey="Celermajer, David S" sort="Celermajer, David S" uniqKey="Celermajer D" first="David S." last="Celermajer">David S. Celermajer</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Sydney Medical School, University of Sydney, NSW</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Australie</country>
</affiliation>
</author>
<author><name sortKey="Jouven, Xavier" sort="Jouven, Xavier" uniqKey="Jouven X" first="Xavier" last="Jouven">Xavier Jouven</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Cardiology, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Maputo Heart Institute (ICOR), Maputo, Mozambique  University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Lancet : (British edition)</title>
<title level="j" type="abbreviated">Lancet : (Br. ed.)</title>
<idno type="ISSN">0140-6736</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Heart disease</term>
<term>Medicine</term>
<term>Rheumatism</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Rhumatisme</term>
<term>Médecine</term>
<term>Cardiopathie</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Médecine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Rheumatic heart disease, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250000 deaths per year worldwide. The disease results from an abnormal autoimmune response to a group A streptococcal infection in a genetically susceptible host. Acute rheumatic fever-the precursor to rheumatic heart disease-can affect different organs and lead to irreversible valve damage and heart failure. Although penicillin is effective in the prevention of the disease, treatment of advanced stages uses up a vast amount of resources, which makes disease management especially challenging in emerging nations. Guidelines have therefore emphasised antibiotic prophylaxis against recurrent episodes of acute rheumatic fever, which seems feasible and cost effective. Early detection and targeted treatment might be possible if populations at risk for rheumatic heart disease in endemic areas are screened. In this setting, active surveillance with echocardiography-based screening might become very important.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0140-6736</s0>
</fA01>
<fA02 i1="01"><s0>LANCAO</s0>
</fA02>
<fA03 i2="1"><s0>Lancet : (Br. ed.)</s0>
</fA03>
<fA05><s2>379</s2>
</fA05>
<fA06><s2>9819</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Rheumatic heart disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MARIJON (Eloi)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>MIRABEL (Mariana)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>CELERMAJER (David S.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>JOUVEN (Xavier)</s1>
</fA11>
<fA14 i1="01"><s1>Paris Cardiovascular Research Centre, INSERM U970, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Cardiology, European Georges Pompidou Hospital</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Paris Descartes University</s1>
<s2>Paris</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Maputo Heart Institute (ICOR), Maputo, Mozambique  University College London</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>2 aut.</sZ>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Sydney Medical School, University of Sydney, NSW</s1>
<s3>AUS</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>953-964</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>5004</s2>
<s5>354000502896370220</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>141 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0137539</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Lancet : (British edition)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Rheumatic heart disease, often neglected by media and policy makers, is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250000 deaths per year worldwide. The disease results from an abnormal autoimmune response to a group A streptococcal infection in a genetically susceptible host. Acute rheumatic fever-the precursor to rheumatic heart disease-can affect different organs and lead to irreversible valve damage and heart failure. Although penicillin is effective in the prevention of the disease, treatment of advanced stages uses up a vast amount of resources, which makes disease management especially challenging in emerging nations. Guidelines have therefore emphasised antibiotic prophylaxis against recurrent episodes of acute rheumatic fever, which seems feasible and cost effective. Early detection and targeted treatment might be possible if populations at risk for rheumatic heart disease in endemic areas are screened. In this setting, active surveillance with echocardiography-based screening might become very important.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Rhumatisme</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Rheumatism</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Reumatismo</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Médecine</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Medicine</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Medicina</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Cardiopathie</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Heart disease</s0>
<s5>04</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Cardiopatía</s0>
<s5>04</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie du système ostéoarticulaire</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Diseases of the osteoarticular system</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Sistema osteoarticular patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Pathologie de l'appareil circulatoire</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Cardiovascular disease</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Aparato circulatorio patología</s0>
<s5>38</s5>
</fC07>
<fN21><s1>107</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004980 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 004980 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Asie
   |area=    AustralieFrV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:12-0137539
   |texte=   Rheumatic heart disease
}}

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024

	Serveur d'exploration sur les relations entre la France et l'Australie
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur les relations entre la France et l'Australie

Rheumatic heart disease

Rheumatic heart disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri